M.D. Anderson Cancer Center: Glioblastoma trials

The registry lists 41 Glioblastoma studies with M.D. Anderson Cancer Center as lead sponsor. 6 are open to participants now and 15 have results posted.

Early Phase 1 2Phase 1 21Phase 2 22No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent GlioblastomaRecruitingNCT07579208Phase 1
• A Phase I/II Study of IVONESCIMAB in Recurrent GlioblastomaRecruitingNCT06672575Phase 1/2
• Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) GlioblastomasRecruitingNCT04623931Phase 2
• Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain TumorsRecruitingNCT04479696Not applicable
• HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsRecruitingNCT03911388Phase 1
• MSC-DNX-2401 in Treating Patients With Recurrent High-Grade GliomaRecruitingNCT03896568Phase 1
• Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT03174197Phase 1/2Results posted
• Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaTerminatedNCT03022578Phase 2Results posted
• Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With GlioblastomaCompletedNCT02661282Phase 1/2Results posted
• Pembrolizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02337686Phase 2Results posted
• Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)CompletedNCT01854554Phase 2Results posted
• Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent GlioblastomaTerminatedNCT01582152Phase 1/2Results posted
• TPI 287 in Patients With Recurrent Glioblastoma MultiformeTerminatedNCT01113463Phase 2Results posted
• Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)TerminatedNCT01110876Phase 1/2Results posted
• Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)CompletedNCT01067469Phase 2Results posted
• Aspirin Prophylaxis for Venous Thromboembolism in GlioblastomaTerminatedNCT00790452Phase 2Results posted
• Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)TerminatedNCT00555399Phase 1/2Results posted
• 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma PatientsCompletedNCT00504660Phase 2Results posted
• Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With GliomasCompletedNCT00412542Phase 2Results posted
• Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma MultiformeCompletedNCT00112502Phase 2Results posted
• Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma MultiformeCompletedNCT00050986Phase 1/2Results posted
• Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent GlioblastomaWithdrawnNCT05879120Phase 2
• Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MRWithdrawnNCT05054400Early Phase 1
• Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05039281Phase 1/2
• Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent GlioblastomaActive, not recruitingNCT04555577Phase 1
• F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing SurgeryCompletedNCT03926507Not applicable
• Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated GlioblastomaCompletedNCT03452930Phase 1
• Mind-Body Intervention in Glioma CouplesActive, not recruitingNCT03244995Not applicable
• FDG PET Imaging in Diagnosing Patients With GlioblastomaCompletedNCT02885272Early Phase 1
• Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaWithdrawnNCT02599090Phase 2
• STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the BrainCompletedNCT01904123Phase 1
• Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)WithdrawnNCT01782976Phase 2
• Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation TherapyTerminatedNCT01430351Phase 1
• SCH-900105 in Recurrent GlioblastomaWithdrawnNCT01189513Phase 1
• Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed GlioblastomaTerminatedNCT00895960Phase 1
• Measuring Non-Enhancing Glioblastoma ProgressionCompletedNCT00777686
• Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaTerminatedNCT00734526Phase 1
• Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase ITerminatedNCT00671801Phase 1
• Dietary Methionine Restriction Plus Temozolomide for Recurrent GBMTerminatedNCT00508456Phase 1
• Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with TemozolomideActive, not recruitingNCT00102648Phase 1
• Temozolomide and SCH66336 for Recurrent Glioblastoma MultiformeCompletedNCT00038493Phase 2